Sandor Schokker

827 total citations
14 papers, 246 citations indexed

About

Sandor Schokker is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Sandor Schokker has authored 14 papers receiving a total of 246 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Surgery. Recurrent topics in Sandor Schokker's work include Gastric Cancer Management and Outcomes (9 papers), Esophageal Cancer Research and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Sandor Schokker is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Esophageal Cancer Research and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Sandor Schokker collaborates with scholars based in Netherlands, United States and Australia. Sandor Schokker's co-authors include Rolf M.F. Berger, Willemijn M. H. Zijlstra, D. Dunbar Ivy, Usha Krishnan, Marcus T.R. Roofthooft, Hans L. Hillege, Johannes M. Douwes, Erika B. Rosenzweig, Hanneke W.M. van Laarhoven and Nadia Haj Mohammad and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Sandor Schokker

14 papers receiving 243 citations

Peers

Countries citing papers authored by Sandor Schokker

Since Specialization

Citations

This map shows the geographic impact of Sandor Schokker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandor Schokker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandor Schokker more than expected).

Fields of papers citing papers by Sandor Schokker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandor Schokker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandor Schokker. The network helps show where Sandor Schokker may publish in the future.

Co-authorship network of co-authors of Sandor Schokker

This figure shows the co-authorship network connecting the top 25 collaborators of Sandor Schokker. A scholar is included among the top collaborators of Sandor Schokker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandor Schokker. Sandor Schokker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Title	Journal	Authors	Indexed citations
1	Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer	Gastric Cancer	M.J.M. van Velzen, Aafke Creemers et al.	17
2	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX	Cancers	Sandor Schokker, Remco J. Molenaar et al.	2
3	Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab	mAbs	Sandor Schokker, Fabrizia Fusetti et al.	15
4	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis	JNCI Journal of the National Cancer Institute	Jessy Joy van Kleef, Emil ter Veer et al.	40
5	Regorafenib in combination with paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): A phase Ib trial with expansion cohort	Annals of Oncology	Mohammed Khurshed, Sandor Schokker et al.	1
6	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.	Journal of Clinical Oncology	Tom van den Ende, Nicolien C. de Clercq et al.	21
7	Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)	Cancers	Sandor Schokker, Jessy Joy van Kleef et al.	4
8	Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis	European Journal of Cancer	Emil ter Veer, Jessy Joy van Kleef et al.	27
9	Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.	Journal of Clinical Oncology	Sandor Schokker, Remco J. Molenaar et al.	5
10	Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): A phase 1 dose escalation study of regorafenib (Reg) combined with paclitaxel (PTX) (REPEAT study)	Annals of Oncology	Sandor Schokker, Ron A. A. Mathôt et al.	1
11	Prognostic and predictive factors for overall survival (OS) in metastatic esophagogastric cancer (EGC): A meta-analysis.	Journal of Clinical Oncology	Emil ter Veer, Jessy Joy van Kleef et al.	1
12	Cerebrovascular, cardiovascular and renal hypertensive disease after hypertensive disorders of pregnancy	Pregnancy Hypertension	Sandor Schokker, Merih I. Baharoglu et al.	19
13	Survival Differences in Pediatric Pulmonary Arterial Hypertension	Journal of the American College of Cardiology	Willemijn M. H. Zijlstra, Johannes M. Douwes et al.	92
14	Children with pulmonary arterial hypertension (PAH) associated with congenital heart disease are treated less intensively with PAH-targeted drugs compared to children with idiopathic/hereditary PAH	European Heart Journal	Willemijn M. H. Zijlstra, Johannes M. Douwes et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact